Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.92 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29950728 | 0.96 | TSHR (1.00) | TSHRCYP1A2HSD17B10CYP2D6MAPT | |
| SCHEMBL7199918 | 0.88 | TSHR (0.85) | TSHRCYP1A2HSD17B10CYP2D6MAPT | |
| SCHEMBL25274647 | 0.88 | TSHR (0.85) | TSHRCYP1A2HSD17B10CYP2D6MAPT | |
| SCHEMBL9307726 | 0.88 | TSHR (0.85) | TSHRCYP1A2HSD17B10CYP2D6MAPT | |
| SCHEMBL12505785 | 0.88 | TSHR (0.70) | TSHRCYP1A2HSD17B10CYP2D6MAPT | |
| SCHEMBL19316994 | 0.88 | TSHR (0.70) | TSHRCYP1A2HSD17B10CYP2D6MAPT | |
| SCHEMBL12092183 | 0.88 | TSHR (0.70) | TSHRCYP1A2HSD17B10CYP2D6MAPT | |
| SCHEMBL21049840 | 0.88 | TSHR (0.70) | TSHRCYP1A2HSD17B10CYP2D6MAPT | |
| SCHEMBL21049848 | 0.88 | TSHR (0.70) | TSHRCYP1A2HSD17B10CYP2D6MAPT | |
| SCHEMBL932686 | 0.88 | TSHR (0.70) | TSHRCYP1A2HSD17B10CYP2D6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367307-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION | TORAY INDUSTRIES, INC. (JP) | 2025-12-04 | — | — | US | disclosed |
| US-20250281630-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION | TORAY INDUSTRIES, INC. (JP) | 2025-09-11 | — | — | US | disclosed |
| US-20250249092-A1 | CONJUGATE OF CAPRIN-1 ANTIBODY LINKED TO IMMUNE ACTIVATOR FOR CANCER TREATMENT | TORAY INDUSTRIES, INC. (JP) | 2025-08-07 | — | — | US | disclosed |
| EP-4548932-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER | Toray Industries, Inc. (JP) | 2025-05-07 | — | — | EP | disclosed |
| US-12274745-B2 | Conjugate of CAPRIN-1 antibody linked to immune activator for cancer treatment | TORAY INDUSTRIES, INC. (JP) | 2025-04-15 | — | — | US | disclosed |
| WO-2025058000-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING, PREVENTING AND/OR DIAGNOSING CANCER | 東レ株式会社 | 2025-03-20 | — | — | WO | disclosed |
| EP-4400121-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER | Toray Industries, Inc. (JP) | 2024-07-17 | — | — | EP | disclosed |
| WO-2023033129-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER | 東レ株式会社 | 2023-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367307-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION | CAPRIN1, NOS1, NCBP1 | TSHR 3527/4885CYP1A2 1254/4885HSD17B10 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.